Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 18/20 | 0.72 |
| ▸ | PIK3C2A | O00443 | 2/20 | 0.61 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.61 |
| ▸ | PRKDC | P78527 | 2/20 | 0.61 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.61 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.61 |
| ▸ | MYC | P01106 | 1/20 | 0.58 |
| ▸ | NAT1 | P18440 | 1/20 | 0.58 |
| ▸ | MAX | P61244 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13155275 | 0.90 | PIK3CG (0.71) | PIK3CG | |
| SCHEMBL5349577 | 0.84 | PIK3CG (1.00) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5349582 | 0.84 | PIK3CG (1.00) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5340669 | 0.82 | PIK3CG (1.00) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5340672 | 0.82 | PIK3CG (1.00) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5340234 | 0.81 | PIK3CG (0.67) | PIK3CG | |
| SCHEMBL5340239 | 0.81 | PIK3CG (0.67) | PIK3CG | |
| SCHEMBL5339386 | 0.78 | PIK3CG (0.75) | PIK3CG | |
| SCHEMBL5342735 | 0.78 | PIK3CG (1.00) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5335930 | 0.77 | PIK3CG (1.00) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-9108980-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | VETDC, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108980-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | VETDC, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150038486-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | ELANCO US INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150038486-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | ELANCO US INC. | 2015-02-05 | — | — | US | disclosed |
| US-8772287-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | VETDC, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772287-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | VETDC, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2013-11-14 | — | — | US | disclosed |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2013-11-14 | — | — | US | disclosed |
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-03-03 | — | — | US | disclosed |
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-03-03 | — | — | US | disclosed |
| US-20110009405-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2011-01-13 | — | — | US | disclosed |
| US-20110009405-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2011-01-13 | — | — | US | disclosed |
| WO-2010110686-A1 | PYRIMIDINYL AND 1,3,5 TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | WO | disclosed |
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | US | disclosed |
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | US | disclosed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| WO-2010074586-A1 | PYRAZOLO[1,5-A]PYRIDINE AND IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | PIK3CA, PIK3R5, PIK3CD | PIK3CG 4/4885PIK3C2A 19/4885PIK3C2B 20/4885 |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | TP53, PNPO, DPYD | PIK3CG 1132/4885PIK3C2A 3068/4885PIK3C2B 3443/4885 |
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PAICS, CCNI, TYMS | PIK3CG 222/4885PIK3C2A 1815/4885PIK3C2B 1376/4885 |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | MTOR, MAPKAP1, PIK3R5 | PIK3CG 42/4885PIK3C2A 14/4885PIK3C2B 8/4885 |
| US-20150038486-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PAICS, CCNI, TYMS | PIK3CG 222/4885PIK3C2A 1815/4885PIK3C2B 1376/4885 |
| US-20110009405-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | TYMP, TYMS, CCNI | PIK3CG 664/4885PIK3C2A 2714/4885PIK3C2B 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.